Tracking Assets is a Key Part of Accountability and Transparency

 

One of the largest sources of financial inefficiency for any construction company are expenditures that can be prevented by consistent asset tracking. On this episode of ThingTech’s Enterprise Asset Intelligence podcast, the CEO of yardz, Jason Perez, sat down with Sean Heath and they discussed the simple way to solve this complex issue.

The most common mistake happens for both owned assets and rented equipment according to Perez.

“People are renting a lot of stuff that they don’t even need to rent, because they don’t even know where their own stuff is,” he said. “That was kind of an interesting segue way of rentals to owned and, really, it’s all about getting the tools regardless of whether you own them or not.”

It may seem that a highly complex solution would be required, but that’s not necessarily the case.

“Our industry is simple. Really simple. The more complex you make it, the less people connect to your solution,” Perez said.

The range of heavy construction project benefits are obvious, but other job sites can leverage the new technology, as well.

“It’s been a big deal for these roofing contractors to be able to go in and go: ‘Hey. Every project we go out, I’m a click of a button away from renting a reach lift, a port-a-potty, and a dumpster. And it takes me about 15 seconds of effort,“ Perez explained.

Misplaced or forgotten equipment is lost revenue that Perez sees on a consistent basis.

“I would say we walk in regularly, 8 months, 6 months, 3 months, you know, it’s months that people are leaving pieces of equipment and we’re talking tens of thousands of dollars that they’re leaving on the table that they could be putting back to the bottom line,” he said.

For the latest news, videos, and podcasts in the Engineering and Construction Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More